Pay in 4 interest-free payments of $36.25 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
of apparent translational significance
CUDC-907 was orally dosed to mice at 100 mg/kg or intravenously dosed at 50 mg/kg once per day in the xenograft tumor model of SU-DHL4 (DLBCL) and A549 (NSCLC)
Tsisanova E
gov/books/NBK548824/ PubMed PMID: 31644131
GGTI-298 TFA - CAS# 1217457-86-7 60002 of apparent translational significanceGGTI 298 TFA, CAS No. 1217457 86 7, is a potent geranylgeranyltransferase I (GGTase I) inhibitor with potential antitumor actrivity. GGTI 298 disrupts MAP kinase activation and G(1) S transition in Ki Ras overexpressing transformed adrenocortical cells. GGTI 298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin dependent kinase inhibitors. A potential mechanism for GGTI 298 antitumor activity. GGTI 298 arrests human tumor
US$ 145.00
US$ 68.00
US$ 68.00
US$ 38.00
US$ 120.00
US$ 38.00